Euro
USD
British Pound
NULL
Product Description
FGFR2 monoclonal Antibody | MB63293 | Bioworld
Host: Mouse
Reactivity: Human, Mouse, Rat
Application: IF, IHC, WB
Application Range: WB 1:2000, IHC 1:150, IF 1:100, FLOW 1:100
Background: The protein encoded by this gene is a member of the fibroblast growth factor receptor family, where amino acid sequence is highly conserved between members and throughout evolution. FGFR family members differ from one another in their ligand affinities and tissue distribution. A full-length representative protein consists of an extracellular region, composed of three immunoglobulin-like domains, a single hydrophobic membrane-spanning segment and a cytoplasmic tyrosine kinase domain. The extracellular portion of the protein interacts with fibroblast growth factors, setting in motion a cascade of downstream signals, ultimately influencing mitogenesis and differentiation. This particular family member is a high-affinity receptor for acidic, basic and/or keratinocyte growth factor, depending on the isoform. Mutations in this gene are associated with Crouzon syndrome, Pfeiffer syndrome, Craniosynostosis, Apert syndrome, Jackson-Weiss syndrome, Beare-Stevenson cutis gyrata syndrome, Saethre-Chotzen syndrome, and syndromic craniosynostosis. Multiple alternatively spliced transcript variants encoding different isoforms have been noted for this gene. [provided by RefSeq]
Storage & Stability: PBS (PH 7.3) containing 1% BSA, 50% glycerol and 0.02% sodium azide.
Specificity: fibroblast growth factor receptor 2
Molecular Weight: 89.7 kDa (Predicted)
Note: For research use only, not for use in diagnostic procedure.
Alternative Names: BBDS; BEK; BFR-1; CD332; CEK3; CFD1; ECT1; JWS; K-SAM; KGFR; TK14; TK25
Immunogen: Full length human recombinant protein of human FGFR2 (NP_000132) produced in HEK293T cell.
Conjugate: Unconjugated
Modification: Unmodification
Purification & Purity: Purified from mouse ascites fluids or tissue culture supernatant by affinity chromatography (protein A/G)
Pathway: N/A
